Brokerages Expect Zynex Inc. (NYSE:ZYXI) to Post $0.07 EPS

Equities analysts expect Zynex Inc. (NYSE:ZYXI) to announce $0.07 earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Zynex’s earnings, with the highest EPS estimate coming in at $0.08 and the lowest estimate coming in at $0.06. Zynex reported earnings per share of $0.06 in the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Zynex will report full-year earnings of $0.40 per share for the current financial year, with EPS estimates ranging from $0.37 to $0.47. For the next fiscal year, analysts expect that the company will report earnings of $0.78 per share, with EPS estimates ranging from $0.55 to $0.97. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Zynex.

Zynex (NYSE:ZYXI) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02. The company had revenue of $15.23 million during the quarter, compared to analyst estimates of $15.07 million.

Separately, HC Wainwright cut Zynex from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 19th.

Zynex stock traded up $1.46 during midday trading on Thursday, reaching $24.64. The company’s stock had a trading volume of 433,573 shares, compared to its average volume of 684,271. Zynex has a fifty-two week low of $7.12 and a fifty-two week high of $27.00. The business has a 50-day simple moving average of $21.17 and a 200-day simple moving average of $13.66.

About Zynex

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device.

Recommended Story: Why Dividend Stocks May Be Right for You

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with's FREE daily email newsletter.